Background: Urinary stones are one of the most common and earliest known human diseases. Extracorporeal shock wave lithotripsy (ESWL) is known as the most common method for treating urinary stones less than 20-25 mm. The aim of this study was to evaluation the success rate of ESWL in patients with urinary stones.Methods: In this cross-sectional descriptive study 200 patients with urinary stones between 7-25 mm which were candidates for lithotripsy, enrolled in the study. Patients with coagulation disorders, urinary or other organ transplantation, pregnant women, uncontrolled blood pressure patients, and those who are contraindicated for drug use have been excluded from the study. The process was carried out by an operator and by the Dornier Compact Delta II lithotriptor. Two weeks later, the patients were re-visited, and ultrasound was performed, and the success rate of stones was measured and recorded and classified in three groups complete response, partial response and failure in treatment. Collected data analysed by statistical methods in SPSS version 19.Results: Efficacy of Arian 101 lithotriptor in removing of renal stones, were found to be 74% complete response, 25.5% partial response while 0.5% of subjects had no response. There was significant positive correlation between the size of stones before and after lithotripsy (r=0.49, p=0.001). In stones upper than 10 mm, the upper calices stones had 100% complete response. Also, in stones lower than 10 mm, the upper calices stones had 100% complete response.Conclusions: The results showed that Dornier Compact Delta II lithotriptor has more efficacy in treatment of stones. In stones below 10 mm, the success rate of treatment was generally higher, especially in the upper calices stones and pelvic. In stones larger than 10 mm, the success rate was slightly lower, but in the case of upper calices stones, the complete response was 100%.
Background: Bladder cancer is the most common cancer of the urethra and genital tract and is ranked ninth in terms of its incidence. The aim of this study was to investigate the clinical and laboratory characteristics of patients with bladder cancer in Ardabil province.Methods: This is a cross-sectional study that has been done on 81 patients with bladder cancer. Necessary information such as age, sex, blood type, RH, family history of bladder cancer, smoking, drug use, tumor stage and grade and type of tumor were collected from the patient's hospital record or by telephone interview.Results: Sixty seven patients (82.7%) were male. The mean age of patients was 66.9±15.02 years. The blood group A, was the most common type of blood. (39.5%) of all patients, 54.3% had cigarette smoking and 47(58%) live in city. The most common type of tumor grade was high-grade papillary urethral carcinoma (48.1%).The most common stages of the tumor was Ta (40.7%) and the most common clinical manifestation was hematuria (90.1%). 27 patients (33.3%) had a delay of more than 3 months between observation of hematuria and cystoscopy.Conclusions: The findings showed that the most common grade and stage of the tumor in patients were high-grade papillary urethral carcinoma and Ta; the most prevalent clinical presentation was hematuria; the prevalence of the disease was higher among males, at ages older than 70 years old, in people with a blood type A, and among people living in urban areas; a study with bigger sample size should be done in future in the country Iran.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.